Specific and Potent RNA Interference in Terminally Differentiated Myotubes*

Christopher E. YiDagger , Janine M. BekkerDagger , Gaynor MillerDagger , Kent L. Hill§, and Rachelle H. CrosbieDagger §||

From the Dagger  Department of Physiological Science, University of California, Los Angeles, California 90025, § Molecular Biology Institute, University of California, Los Angeles, California 90025, and  Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, California 90025

Received for publication, June 14, 2002, and in revised form, October 18, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Double-stranded RNA (dsRNA) interference is a potent mechanism for sequence-specific silencing of gene expression and represents an invaluable approach for investigating gene function in normal and diseased states as well as for drug target validation. Here, we report that skeletal muscle myoblasts and terminally differentiated myotubes are susceptible to RNA interference. We employed an approach in which dsRNA is generated by cellular transcription from plasmids containing long (1 kilobase) inverted DNA repeats of the target gene rather than using dsRNA synthesized in vitro. We show that gene silencing by this method is effective for endogenously expressed genes as well as for exogenous reporter genes. An analysis of the expression of several endogenous genes and exogenous reporters demonstrates that the silencing effect is specific for the target gene containing sequences within the inverted repeat. Our method eliminates the need to chemically synthesize dsRNA and is not accompanied by global repression of gene expression. Furthermore, we show for the first time that sequence-specific dsRNA-mediated gene silencing is possible in differentiated, multinucleated skeletal muscle myotubes. These findings provide an important molecular tool for the examination of protein function in terminally differentiated muscle cells and provide alternative approaches for generating disease models.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The availability of whole genome sequences for humans and model organisms has greatly facilitated the identification of genes responsible for inherited human disease. In the post-genomics era, efforts to understand the molecular basis of disease will be limited primarily by the ability to determine the function of proteins encoded by candidate disease genes and to evaluate novel drug targets. The ability to silence expression of specific genes is a powerful mechanism for analysis of gene function. Although targeted gene disruption via homologous recombination is possible in mammals, currently available strategies are costly and time-consuming. The generation of knock-out animal models may also be confounded by unanticipated splice variants that produce functional proteins, despite the removal of targeted exons (1). Furthermore, when embryonic lethality results from gene deletion (2), it may be impossible to evaluate the role of a target protein in fully differentiated cells and adult tissues.

Sequence-specific gene silencing initiated by the presence of aberrant RNA was first observed in plants containing inverted transgenes and referred to as post-transcriptional gene silencing (3, 4). A similar gene silencing phenomenon was observed in Caenorhabditis elegans where insightful genetic studies demonstrate that silencing was mediated by double-stranded RNA and occurred at the level of mRNA abundance (5, 6). The term double-stranded RNA interference (dsRNAi)1 was coined to describe this RNA-mediated genetic interference. The use of RNAi to target specific mRNAs for degradation provides an alternative method for targeted gene silencing and has now been shown to function in a variety of organisms including nematodes, planaria, trypanosomes, hydra, zebrafish, and Drosophila (5-14). In these systems, the presence of dsRNA composed of protein coding sequence induces degradation of single-stranded mRNA that is complementary to the dsRNA (5, 6, 15, 16). Genetic screens for RNAi-resistant mutants in C. elegans has led to the identification of some components of the RNAi machinery including an RNA-dependent RNA polymerase, eIF-2C, and RNase D (17-19). Although the precise mechanism of RNAi is still unclear, the process has been heralded as revolutionary because of its specificity, catalytic features, and effectiveness in comparison with traditional sense or antisense knock-out technology (20).

Despite the broad species specificity of RNAi (16), its utility for examining gene function in mammalian cells has remained somewhat dubious because of nonspecific repression of gene expression that is induced by cellular responses to cytoplasmic duplex RNA in many mammalian cell lines (21-25). A major component of this response is presumed to be the dsRNA-dependent protein kinase PKR, which upon activation by dsRNA longer than 30 nucleotides, phosphorylates eIF-2alpha , leading to global down-regulation of protein translation (21, 22). In an important advance, Elbashir et al. (23) and Caplen et al. (24) recently showed that by limiting the length of the synthetic dsRNA to <30 bp, sequence-specific RNAi can be achieved in several commonly used non-differentiated cultured mammalian cell lines. These studies demonstrate that the machinery responsible for sequence-specific RNAi is present in these cells, although the magnitude of the specific decrease in target gene expression varies considerably depending upon the cell type examined and choice of target gene (23, 24, 26). When the length of the dsRNA duplex exceeds ~30 nucleotides, the specificity of dsRNA-induced gene silencing is lost and genes unrelated to the dsRNA duplex are also down-regulated (23, 24).

Because of our interest in gene products involved in the pathogenesis of muscular dystrophy, we analyzed the efficacy of dsRNAi in cultured skeletal muscle myoblasts and myotubes. To date, nearly all RNAi approaches with mammalian cells have involved the introduction of in vitro synthesized dsRNA into the cytoplasm of undifferentiated cells (23, 26, 27). In this study, we use an alternate approach of introducing plasmid DNA encoding inverted repeats of a target sequence into cultured murine muscle cells. This approach has been dramatically successful in other non-mammalian systems (13) and has recently been shown to be effective for RNAi in embryonic cell lines (28). Using this method, we demonstrate that RNA interference is effective and specific in cultured mammalian muscle cells.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Plasmid Expression Constructs-- A human dyxin expression construct was prepared by PCR amplification of the dyxin open reading frame (GenBankTM accession number AF216709) (29) using primers containing appropriate restriction sites for subcloning into the mammalian expression vector pcDNA3 (Amersham Biosciences) A human sarcospan expression construct was prepared by PCR amplification of the sarcospan open reading frame from a human skeletal muscle cDNA library (Clontech, Palo Alto, CA) (31). Both the dyxin (pcDNA.dyxin) and the sarcospan (pcDNA.SSPN) constructs were engineered to encode a Myc tag at the COOH terminus followed by a stop codon. For dsRNA expression constructs, standard cloning methods were used to place oppositely oriented copies of the dyxin open reading frame at either end of the GFPmut3b gene (GenBankTM accession number AF110459.1) (32). This construct was inserted into the multicloning site of pcDNA3 to generate pcDNA.dyxin.dsRNA with the 5' copy of the dyxin gene oriented in the forward direction (Fig. 3). A similar dsRNA expression plasmid was engineered using inverted repeats of the GFPmut3b gene (nucleotides 1-714) (32). The sequences of all constructs were verified by direct DNA sequence analysis performed by the DNA Core Facility at the University of Iowa (Iowa City, IA).

Cell Culture Strains and Media-- C2C12 myoblasts, strain C3H (American Type Cell Culture, Manassas, VA) (33, 34), were grown and maintained in Dulbecco's modified essential medium (DMEM, Sigma) with 10% fetal bovine serum and 1% L-glutamine, and 1% penicillin-streptomycin C2C12 myoblasts were differentiated into myotubes by incubating in DMEM with 2% horse serum for 5-7 days as described previously (34).

Transfection of C2C12 Myoblasts-- C2C12 cells were trypsinized after reaching 90% confluency on a 150-mm plate and resuspended in phosphate-buffered saline lacking CaCl2 and MgCl2 (1.4 mM NaCl, 0.27 mM KCl, 1 mM Na2HPO4, and 0.18 mM dibasic phosphate, pH 7.4). Myoblasts were transfected with 5 µg of plasmid DNA by electroporation (340 V at 950 microfarads) in 1-cm electroporation cuvettes and electroporated with a Bio-Rad Gene Pulser II (Bio-Rad, Hercules, CA). Time constants ranged from 16 to 17 ms. Immediately after electroporation, cells were resuspended in complete medium and plated in 35-mm culture plates as described previously (35).

Transfection of C2C12 myotubes-- Clonfectin (Clontech, Palo Alto, CA) was diluted to 1 mg/ml in 10 mM HEPES-NaCl-buffered saline, and 5 µg was combined with 5 µg of plasmid DNA in serum-free DMEM. The liposome plus DNA mixture was incubated for 30 min and then added to myotubes grown on a 35-mm culture dish with 2 ml of serum- free DMEM. Myotubes were treated with the Clonfectin solution for 2 h at 37 °C, 5% CO2. After transfection, the medium was aspirated and the cells were washed with phosphate-buffered saline and allowed to grow in fresh complete DMEM. To quantitate transfection efficiency, myotubes were transfected with pEGFP-C3 plasmid (Clontech, Palo Alto, CA), which encodes green fluorescent protein (GFP). Myotubes were viewed under a Zeiss Axiovert 200 inverted fluorescence microscope. Percent transfection efficiency was determined by counting the number of GFP-positive cells relative to total cell number. Under these conditions, over 85% transfection efficiency was routinely achieved.

Western Blot Analysis-- For protein lysates, myoblasts, and myotubes were washed with phosphate-buffered saline and lysed in lysis buffer (300 µl of 50 mM HEPES, pH 7.8, 300 mM NaCl, 1% Nonidet P-40, 1.2 mM EDTA, 5 mM MgCl2, 0.1 mM phenylmethylsulfonyl fluoride, 0.75 mM benzamidine, 0.5 µg/ml aprotinin, and 0.5 µg/ml leupeptin). Protein samples (30 µg/lane) were resolved on a 10% SDS-polyacrylamide gel and transferred to polyvinyl difluoride membrane (Immobilin-P, Millipore, Bedford, MA) as described previously (35). To detect heterologous Myc-tagged proteins, immunoblots were probed with mouse monoclonal antibodies to the Myc tag (9E10, 1:1000 dilution, Sigma). For dyxin immunoblotting, membranes were probed with affinity-purified polyclonal antibody (rabbit 2, 1:500 dilution) generated against a COOH-terminal peptide-(KGQLLCPTCSKSKRS). The monoclonal antibody E7 directed against beta -tubulin was developed previously (30) and obtained from the Developmental Studies Hybridoma Bank maintained by the Department of Biological Sciences, University of Iowa (Iowa City, IA). E7 supernatant was used at a 1:5000 dilution to detect beta -tubulin on immunoblots. Antibodies to vinculin (1:250, Sigma) and eIF-2alpha (1:100, Santa Cruz Biotechnology Inc.) were used for immunoblotting as indicated by the manufacturer. Following incubation with the primary antibodies, blots were probed with either anti-mouse or anti-rabbit horseradish peroxidase-conjugated secondary antibodies (1:5000 dilution, Amersham Biosciences) and developed using enhanced chemiluminescence (SuperSignal, Pierce, Rockford, IL).

Northern Blotting-- Total RNA was isolated from transfected C2C12 cells using TRIzol (Invitrogen) according to the manufacturer's instructions. Total RNA (2 µg) was fractionated by formaldehyde gel and subjected to Northern blot analysis using probes, representing the full-length dyxin, beta -actin, and glyceraldehyde-3-phosphate dehydrogenase.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Inherited muscle disease provides an excellent example of a field where the identification of candidate disease genes is outpacing efforts to understand function of the corresponding gene products. We investigated whether RNAi could be used for sequence-specific gene silencing in muscle cells as a method for analysis of gene function. As a target gene, we chose a novel "LIM and cysteine-rich domain" gene (LMCD1) (29) (GenBankTM accession number NM014583), also known as dyxin (GenBankTM AF216709). Dyxin has two tandem LIM domains in its COOH-terminal region and is highly expressed in skeletal muscle (29). Although the precise function of dyxin is unknown, it is postulated to be involved in DNA-protein interactions during skeletal muscle development (29).

As a model system, we employed C2C12 cells, a well established murine skeletal muscle cell line (33). C2C12 cells can be maintained in culture as undifferentiated myoblasts or can be induced to fuse and assemble into terminally differentiated, multinucleated myotubes in low mitogen medium (33). Immunoblots of whole cell lysates from C2C12 myoblasts and myotubes were probed with affinity-purified anti-dyxin polyclonal antibodies (Fig. 1). As shown in Fig. 1, dyxin is expressed in mature differentiated myotubes but not in myoblasts. Thus, by employing both myoblasts and myotubes, we are able to assess the utility of RNAi for silencing the expression of exogenous reporter genes (recombinant dyxin in myoblasts) as well as endogenously expressed genes (dyxin in myotubes).


View larger version (11K):
[in this window]
[in a new window]
 
Fig. 1.   Dyxin expression is developmentally regulated and is only expressed upon differentiation of myoblasts into mature myotubes. Protein extracts (30 µg) from murine C2C12 myoblasts and differentiated myotubes were electrophoretically separated in 10% SDS-polyacrylamide gels and transferred to polyvinyl difluoride membrane. Blots were stained with affinity-purified rabbit polyclonal antibodies against dyxin, a 48-kDa LIM domain protein (29, 30) (GenBankTM NM014583). Molecular size standards are indicated on the left (×103 Da).

To demonstrate that exogenous dyxin expression is possible in myoblasts, a Myc-tagged human dyxin cDNA plasmid (pcDNA.dyxin) was introduced into C2C12 myoblasts by electroporation. Immunoblots of protein lysates from transfected C2C12 cells were stained with either anti-dyxin antibodies (Fig. 2) or monoclonal antibodies to the Myc tag (data not shown). Dyxin protein was not detected in mock-transfected cells (Fig. 2, lane 1) but is expressed at high levels 30 h post-transfection with pcDNA.dyxin (Fig. 2, lane 2).


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 2.   Expression of dyxin dsRNA leads to specific loss of dyxin expression in cultured myoblasts. C2C12 myoblasts were mock-transfected (lane 1, Mock) or transfected with plasmid pcDNA.dyxin encoding dyxin (lane 2, DYX) or plasmid pcDNA.dyxin.dsRNA, encoding dyxin-inverted repeats (lane 3, DIR). Parallel samples were co-transfected with pcDNA.dyxin and pcDNA.dyxin.dsRNA (lane 4, DYX + DIR). As a control for specificity, cells were co-transfected with pcDNA.dyxin and pcDNA.GFP.dsRNA containing GFP-inverted repeats (lane 5, DYX + GIR). Dyxin expression is ablated by expression of dyxin dsRNA but not by GFP dsRNA. Cell lysates were harvested 24 h post-transfection and analyzed for dyxin levels by immunoblotting with affinity-purified rabbit polyclonal antibodies against dyxin (top panel). Identical blots were probed with monoclonal antibodies to beta -tubulin, vinculin, and eIF-2alpha as illustrated. Expression of dyxin dsRNA did not perturb protein levels of these endogenous proteins. Molecular size markers are indicated (×103 Da).

Previous efforts to use RNAi for sequence-specific gene silencing in cultured mammalian cells have primarily employed dsRNA molecules that were produced and annealed in vitro and then introduced into the cytoplasm of cultured cells by injection or liposome-mediated transfection (23, 24, 26). When the length of the synthetic dsRNA exceeds 30 bp, the target cells are found to exhibit a generalized suppression of gene expression (23, 24). This nonspecific inhibition of gene expression is presumed to result from interferon-response pathways that are activated by the presence of dsRNA injected into the cytoplasm, a process that may mimic the response of the cell to viral dsRNA (23, 24, 36). In this study, we employed an alternative strategy in which the cell's own transcription machinery transcribes inverted DNA repeats, producing dsRNA within the cell. For these experiments, we generated a dyxin dsRNA expression vector (pcDNA.dyxin.dsRNA) containing inverted copies of a 1-kilobase portion of the dyxin open reading frame separated by 700 bp of nonspecific "spacer" DNA (Fig. 3).


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 3.   Schematic diagram of the dyxin dsRNA construct used to block dyxin expression by dsRNA-interference. The complete dyxin cDNA (nucleotides 1-1091) was cloned into a pcDNA3 mammalian expression vector in the forward and reverse orientations as illustrated. This construct, pcDNA.dyxin.dsRNA, is designed to generate a double-stranded, step-loop RNA upon transcription. The cytomegalovirus promoter (CMV) is located upstream of the double-inverted dyxin repeats. A similar dsRNAi expression plasmid was engineered using inverted repeats of GFP, pcDNA.GFP.dsRNA.

To test the efficacy of RNAi on exogenous dyxin expression, C2C12 myoblasts were co-transfected with pcDNA.dyxin together with pcDNA.dyxin.dsRNA. Whole cell lysates were assayed for dyxin expression by immunoblotting (Fig. 2). These experiments demonstrate that exogenous dyxin expression is blocked by expression of the dyxin dsRNA construct. The specificity of this gene silencing was tested using three separate approaches. First, the expression of several endogenous genes was examined in cells transfected with pcDNA.dyxin.dsRNA. As shown in Fig. 2, dyxin dsRNA has no effect on the expression of beta -tubulin, vinculin, or eIF-2alpha . Therefore, gene silencing is specific for the target gene. We next asked whether dyxin expression was affected by a non-homologous dsRNA construct. For this purpose, we constructed a plasmid (pcDNA.GFP.dsRNA) containing inverted repeats of the GFP open reading frame. Dyxin remains abundantly expressed in myoblasts co-transfected with pcDNA.dyxin and pcDNA.GFP.dsRNA (Fig. 2, lane 5), demonstrating that GFP dsRNA has no effect on exogenous dyxin expression. As shown earlier for dyxin dsRNA, GFP dsRNA also has no effect on endogenous expression of beta -tubulin, vinculin, or eIF-2alpha (Fig. 2, lane 5). As an additional test of the specificity of RNAi in myoblasts, we examined the effect of dyxin dsRNA on the expression of another exogenous reporter gene. As a reporter gene, we used sarcospan (SSPN), a component of the dystrophin-glycoprotein complex (31, 35, 37). Myoblasts do not normally express SSPN (data not shown), but cells transfected with a sarcospan cDNA express high levels of sarcospan protein (Fig. 4, lane 1). Expression of sarcospan was not affected by co-expression of dyxin.dsRNA (Fig. 4, lane 2).


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 4.   Specificity of double-stranded RNA interference. Myoblasts were transfected with an expression vector encoding Myc-tagged human sarcospan, pcDNA.SSPN (lanes 1 and 3, SSPN), or co-transfected with pcDNA.SSPN and pcDNA.dyxin.dsRNA (lanes 2 and 4, SSPN + DIR). Immunoblots of protein lysates were separately stained with 9E10 anti-Myc antibodies to detect SSPN (lanes 1 and 2) or monoclonal antibody E7 (42) to detect beta -tubulin (lanes 3 and 4). Expression of dyxin dsRNA does not affect expression of the heterologous reporter SSPN or endogenous beta -tubulin. Molecular mass markers are indicated (×103 Da).

A key feature of RNA interference is that it exerts its effect at the post-transcriptional level by destruction of targeted mRNA (for review see Ref. 16). To test whether the loss of dyxin protein occurred at the level of mRNA abundance, we analyzed dyxin mRNA levels by Northern blotting. Total RNA was prepared from the samples analyzed previously for dyxin protein expression. Northern blots were probed with a full-length dyxin cDNA probe. As shown in Fig. 5, a 1.35-kilobase dyxin transcript is expressed in C2C12 myoblasts transfected with pcDNA.dyxin, but this dyxin mRNA is dramatically reduced in myoblasts co-transfected with pcDNA.dyxin and pcDNA.dyxin.dsRNA (Fig. 5, lane 4). As a control for specificity, dyxin mRNA levels are not affected by co-transfection with a non-homologous dsRNA construct (pcDNA.GFP.dsRNA) (Fig. 5, lane 5). Northern blots hybridized with probes for beta -actin (Fig. 5, lower panel) and glyceraldehyde-3-phosphate dehydrogenase (data not shown) further demonstrate that silencing is specific for dyxin.


View larger version (69K):
[in this window]
[in a new window]
 
Fig. 5.   Dyxin dsRNA-induced gene silencing occurs at the level of mRNA abundance. Northern blots containing 2 µg of total RNA from mock (lane 1, Mock), pcDNA.dyxin (lane 2, DYX), or pcDNA.dyxin.dsRNA (lane 3, DIR) transfected myoblasts. Parallel samples were taken from cells co-transfected with pcDNA.dyxin and pcDNA.dyxin.dsRNA (lane 4, DYX + DIR). As a control for specificity, RNA was analyzed from myoblasts co-transfected with pcDNA.dyxin and pcDNA.GFP.dsRNA (lane 5, DYX + GIR). Blots were hybridized with dyxin (top panel) and beta -actin (bottom panel) probes.

The ability to silence specific genes in mammalian cells holds great promise for uncovering the function of proteins that are known to be defective in certain inherited diseases. However, many disease genes are expressed only in terminally differentiated cells and tissues. For example, components of the dystrophin-glycoprotein complex are required for normal muscle function and prevention of Duchenne muscular dystrophy (38) but are expressed only upon differentiation of myoblasts into myotubes (39). To determine whether RNAi can be used for sequence-specific gene silencing in differentiated mammalian cells, we induced the differentiation of C2C12 myoblasts into skeletal muscle myotubes in culture. Myotubes possess fully functional sarcomeres, exhibit contractile properties in culture, and are important models for mammalian skeletal muscle physiology (33). We introduced the dyxin dsRNA expression vector (pcDNA.dyxin.dsRNA) into myotubes by liposome-mediated transfection. Whole myotube protein lysates were analyzed at 0, 12, and 24 h post-transfection by Western blotting with affinity-purified anti-dyxin antibodies (Fig. 6). Endogenous dyxin expression in myotubes was completely abolished 12 and 24 h after transfection with the dyxin dsRNA expression vector (Fig. 6). Dyxin levels were constant for all mock-treated samples (Fig. 3) (data not shown). As is the case for myoblasts, dyxin.dsRNA-mediated gene silencing is specific to dyxin because beta -tubulin, vinculin, and eIF-2alpha expression remained constant in all samples (Fig. 6) (data not shown).


View larger version (69K):
[in this window]
[in a new window]
 
Fig. 6.   dsRNA-induced silencing of endogenous dyxin in differentiated myotubes. C2C12 myoblasts were differentiated into multinucleated myotubes in culture as described under "Experimental Procedures." Myotubes were transfected by liposome transfection with pcDNA.dyxin.dsRNA, and cellular lysates were analyzed for dyxin expression 0, 12, and 24 h after transfection as indicated. Immunoblots were probed with anti-dyxin polyclonal antibody (left panel) or anti-beta -tubulin (E7) monoclonal antibody (30) (right panel). Molecular mass markers are indicated (×103 Da).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Skeletal muscle fibers are specialized multinucleated cells with well organized contractile filaments. Investigating the function of muscle-specific gene products is complicated by the limitations of traditional cell lines, which lack the contractile apparatus and therefore lack many muscle-specific proteins. Although cultured myotubes provide an excellent model for studying skeletal muscle physiology, the lack of a method to easily eliminate gene expression in these cells has restricted in vivo analysis of protein function. RNAi offers a number of advantages over gene disruption, because it is rapid, potent, and can be achieved with a fraction of the effort required for generating knock-out animal models. Recent ground-breaking experiments have demonstrated that sequence-specific RNAi is feasible in certain types of undifferentiated cultured mammalian cells using chemically synthesized or in vitro generated duplex RNAs (23, 26, 27, 40). To extend these studies to terminally differentiated myofibers, we tested a method whereby plasmid DNA containing large inverted repeats of a target mRNA is introduced into myoblasts and myotubes. In this way, dsRNA is generated intracellularly by transcription from the expression vector. We demonstrate that gene silencing induced by this method results in a loss of target gene expression without perturbing overall gene expression. Importantly, we show that the target mRNA can be an endogenous transcript or an exogenous reporter gene and that the loss of the target mRNA is correlated with concomitant loss of target protein. Only the target gene is affected, and inverted repeats containing non-relevant sequences have no effect on target gene expression. In addition, we demonstrate that gene silencing by this approach is effective in mature differentiated skeletal muscle myotubes.

Although the mechanism of dsRNA-mediated gene silencing observed here in mammalian muscle cells remains to be determined, several lines of evidence suggest that this is occurring through a phenomenon mechanistically related to RNA interference pathways that have been characterized in C. elegans, Drosophila, and other systems (16). First, the loss of target gene expression is not accompanied by global down-regulation of protein synthesis. Second, target gene silencing is sequence-specific, because non-homologous dsRNA does not interfere with target gene expression. Third, silencing of the target gene occurs at the level of mRNA abundance. Importantly, the ability to silence endogenously expressed genes demonstrates the utility of this approach for examining the function of proteins that are only expressed in differentiated muscle cells.

Recent work from several laboratories indicates that the effectiveness of long dsRNA for inducing sequence-specific RNAi in cultured mammalian cells varies from cell type to cell type (23, 26, 27, 40). During preparation of this paper, Paddison and colleagues (28) report using a 500-nucleotide synthetic luciferase dsRNA to knockdown expression of an exogenous reporter gene (firefly luciferase) in murine myoblasts. Our results compliment and extend this work by demonstrating potent and sequence-specific silencing of endogenous gene expression in both myoblasts and myotubes. Together, these results suggest that murine myoblasts and myotubes may be more susceptible to sequence-specific RNAi than other mammalian cell types thus far tested as has been previously been reported for embryonic cell lines (28).

We have shown that double-stranded RNA-induced gene silencing is possible in terminally differentiated muscle cell lines. This represents the first example of dsRNA-induced gene silencing in terminally differentiated mammalian cells and demonstrates that the target gene can be an endogenous transcript that is expressed only upon cellular differentiation. These findings provide an alternative to traditional gene "knock-out" studies for generating models of inherited muscle disease. It has recently been reported that RNAi induced by short synthetic-interfering RNA duplexes (siRNA) can be used to knockdown expression of several endogenous genes in mammalian cell lines (23, 24, 41). Our studies extend these findings by demonstrating that sequence-specific dsRNA-mediated gene silencing can be used for functional analysis of muscle gene products within the context of a biologically relevant cell culture model for mammalian muscle. With advances in gene-silencing techniques, diseases that are caused by genetic mutations leading to loss of protein expression (i.e. recessive muscular dystrophies) can be investigated with greater ease.

    ACKNOWLEDGEMENTS

We thank K. M. Lipman for technical assistance.

    FOOTNOTES

* This work was supported by Grant 1RO1AR48179-01 from the National Institutes of Health (to R. H. C.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

|| To whom correspondence should be addressed: University of California, Life Sciences Bldg. 5804, 621 Charles E. Young Dr., S., Los Angeles, CA 90025. Tel.: 310-794-2103; Fax: 310-206-3987; E-mail: rcrosbie@physci.ucla.edu.

Published, JBC Papers in Press, November 5, 2002, DOI 10.1074/jbc.M205946200

    ABBREVIATIONS

The abbreviations used are: dsRNAi, double-stranded RNA interference; dsRNA, double-stranded RNA; eIF, eukaryotic initiation factor; DMEM, Dulbecco's modified Eagle's medium; GFP, green fluorescent protein; SSPN, sarcospan.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Huang, P. L., Dawson, T. M., Bredt, D. S., Snyder, S. H., and Fishman, M. C. (1993) Cell 75, 1273-1286[Medline] [Order article via Infotrieve]
2. Williamson, R. A., Henry, M. D., Daniels, K. J., Hrstka, R. F., Lee, J. C., Sunada, Y., Ibraghimov-Beskrovnaya, O., and Campbell, K. P. (1997) Hum. Mol. Genet. 6, 831-841[Abstract/Free Full Text]
3. Que, Q., and Jorgensen, R. A. (1998) Dev. Genet. 22, 100-109[CrossRef][Medline] [Order article via Infotrieve]
4. Jorgensen, R. A., Cluster, P. D., English, J., Que, Q., and Napoli, C. A. (1996) Plant Mol. Biol. 31, 957-973[Medline] [Order article via Infotrieve]
5. Montgomery, M. K., Xu, S., and Fire, A. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 15502-15507[Abstract/Free Full Text]
6. Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., and Mello, C. C. (1998) Nature 391, 806-811[CrossRef][Medline] [Order article via Infotrieve]
7. Kennerdell, J. R., and Carthew, R. W. (1998) Cell 95, 1017-1026[Medline] [Order article via Infotrieve]
8. Timmons, L., and Fire, A. (1998) Nature 395, 854[CrossRef][Medline] [Order article via Infotrieve]
9. Wargelius, A., Ellingsen, S., and Fjose, A. (1999) Biochem. Biophys. Res. Commun. 263, 156-161[CrossRef][Medline] [Order article via Infotrieve]
10. Bahramian, M. B., and Zarbl, H. (1999) Mol. Cell. Biol. 19, 274-283[Abstract/Free Full Text]
11. Lohmann, V., Korner, F., Koch, J., Herian, U., Theilmann, L., and Bartenschlager, R. (1999) Science 285, 110-113[Abstract/Free Full Text]
12. Misquitta, L., and Paterson, B. M. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 1451-1456[Abstract/Free Full Text]
13. Ngo, H., Tschudi, C., Gull, K., and Ullu, E. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 14687-14692[Abstract/Free Full Text]
14. Li, W., Boswell, R., and Wood, W. B. (2000) Dev. Biol. 218, 172-182[CrossRef][Medline] [Order article via Infotrieve]
15. Bosher, J. M., Dufourcq, P., Sookhareea, S., and Labouesse, M. (1999) Genetics 153, 1245-1256[Abstract/Free Full Text]
16. Hammond, S. M., Caudy, A. A., and Hannon, G. J. (2001) Nat. Rev. Genet. 2, 110-119[CrossRef][Medline] [Order article via Infotrieve]
17. Ketting, R. F., Haverkamp, T. H., van Luenen, H. G., and Plasterk, R. H. (1999) Cell 99, 133-141[Medline] [Order article via Infotrieve]
18. Tabara, H., Sarkissian, M., Kelly, W. G., Fleenor, J., Grishok, A., Timmons, L., Fire, A., and Mello, C. C. (1999) Cell 99, 123-132[Medline] [Order article via Infotrieve]
19. Smardon, A., Spoerke, J. M., Stacey, S. C., Klein, M. E., Mackin, N., and Maine, E. M. (2000) Curr. Biol. 10, 169-178[CrossRef][Medline] [Order article via Infotrieve]
20. Bosher, J. M., and Labouesse, M. (2000) Nat. Cell Biol. 2, E31-E36[CrossRef][Medline] [Order article via Infotrieve]
21. Clemens, M. J. (1997) Int. J. Biochem. Cell Biol. 29, 945-949[CrossRef][Medline] [Order article via Infotrieve]
22. Stark, G. R., Kerr, I. M., Williams, B. R., Silverman, R. H., and Schreiber, R. D. (1998) Annu. Rev. Biochem. 67, 227-264[CrossRef][Medline] [Order article via Infotrieve]
23. Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., and Tuschl, T. (2001) Nature 411, 494-498[CrossRef][Medline] [Order article via Infotrieve]
24. Caplen, N. J., Parrish, S., Imani, F., Fire, A., and Morgan, R. A. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 9742-9747[Abstract/Free Full Text]
25. Paddison, P. J., Caudy, A. A., Bernstein, E., Hannon, G. J., and Conklin, D. S. (2002) Genes Dev. 16, 948-958[Abstract/Free Full Text]
26. Wianny, F., and Zernicka-Goetz, M. (2000) Nat. Cell Biol. 2, 70-75[CrossRef][Medline] [Order article via Infotrieve]
27. Caplen, N. J., Fleenor, J., Fire, A., and Morgan, R. A. (2000) Gene (Amst.) 252, 95-105[CrossRef][Medline] [Order article via Infotrieve]
28. Paddison, P. J., Caudy, A. A., and Hannon, G. J. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 1443-1448[Abstract/Free Full Text]
29. Bespalova, I. N., and Burmeister, M. (2000) Genomics 63, 69-74[CrossRef][Medline] [Order article via Infotrieve]
30. Chu, D. T., and Klymkowsky, M. W. (1989) Dev. Biol. 136, 104-117[Medline] [Order article via Infotrieve]
31. Crosbie, R. H., Heighway, J., Venzke, D. P., Lee, J. C., and Campbell, K. P. (1997) J. Biol. Chem. 272, 31221-31224[Abstract/Free Full Text]
32. Cormack, B. P., Valdivia, R. H., and Falkow, S. (1996) Gene (Amst.) 173, 33-38[CrossRef][Medline] [Order article via Infotrieve]
33. Blau, H. M., Pavlath, G. K., Hardeman, E. C., Chiu, C. P., Silberstein, L., Webster, S. G., Miller, S. C., and Webster, C. (1985) Science 230, 758-766[Medline] [Order article via Infotrieve]
34. Yaffe, D., and Saxel, O. (1977) Nature 270, 725-727[Medline] [Order article via Infotrieve]
35. Crosbie, R. H., Lebakken, C. S., Holt, K. H., Venzke, D. P., Straub, V., Lee, J. C., Grady, R. M., Chamberlain, J. S., Sanes, J. R., and Campbell, K. P. (1999) J. Cell Biol. 145, 153-165[Abstract/Free Full Text]
36. Clemens, M. J., and Elia, A. (1997) J. Interferon Cytokine Res. 17, 503-524[Medline] [Order article via Infotrieve]
37. Crosbie, R. H., Lim, L. E., Moore, S. A., Hirano, M., Hays, A. P., Maybaum, S. W., Collin, H., Dovico, S. A., Stolle, C. A., Fardeau, M., Tome, F. M., and Campbell, K. P. (2000) Hum. Mol. Genet. 9, 2019-2027[Abstract/Free Full Text]
38. Allamand, V., and Campbell, K. P. (2000) Hum. Mol. Genet. 9, 2459-2467[Abstract/Free Full Text]
39. Belkin, A. M., and Burridge, K. (1995) J. Biol. Chem. 270, 6328-6337[Abstract/Free Full Text]
40. Ui-Tei, K., Zenno, S., Miyata, Y., and Saigo, K. (2000) FEBS Lett. 479, 79-82[CrossRef][Medline] [Order article via Infotrieve]
41. Harborth, J., Elbashir, S. M., Bechert, K., Tuschl, T., and Weber, K. (2001) J. Cell Sci. 114, 4557-4565[Abstract/Free Full Text]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.



This Article
Abstract
Full Text (PDF)
All Versions of this Article:
278/2/934    most recent
M205946200v1
Purchase Article
View Shopping Cart
Alert me when this article is cited
Alert me if a correction is posted
Citation Map
Services
Email this article to a friend
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Copyright Permissions
Google Scholar
Articles by Yi, C. E.
Articles by Crosbie, R. H.
Articles citing this Article
PubMed
PubMed Citation
Articles by Yi, C. E.
Articles by Crosbie, R. H.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   Biochemistry and Molecular Biology Education 
Copyright © 2003 by the American Society for Biochemistry and Molecular Biology.